Journal: Clinical and Translational Medicine

Article Title: Diversity and intratumoral heterogeneity in human gallbladder cancer progression revealed by single‐cell RNA sequencing

doi: 10.1002/ctm2.462

Figure Lengend Snippet: Diversity and functionality of tumor‐infiltrating lymphocytes in GC tissues. (A) The t‐SNE plot of the lymphocytes was shown, colored by the cell subgroups as indicated. Resolution used for t‐SNE cell grouping analysis is 2.0. (B) The violin plot of the normalized expression levels of representative biomarkers in each cell subgroup. (C) The normalized expression profile of biomarkers related to distinct cellular biological activities or T cell state was shown. (D) Dot plots of representative cytotoxic, exhausted, regulatory, naïve, and costimulatory signatures in T cells. Z ‐score normalized of GSVA enrichment scores. (E) The averaged proportion of lymphocytes in primary tumor ( n = 4), lymph node metastatic (LN, n = 4), and adjacent normal ( n = 2) tissues was shown, colored by cell subgroups. (F) Comparison of FOXP3+, CD4+, and CD8+ cell proportion in the NET ( n = 4), glandular tumor ( n = 7), and the adjacent normal ( n = 7) tissues. * Paired or # unpaired Student's t ‐test was performed. (G) Comparison of the estimated CD8+ T cell proportion and cytotoxicity score signature in 10 paired tumor and normal tissues of GSE139682 database. Two‐tailed paired Student's t ‐test. (H) The t‐SNE plot of B cells was shown, colored by cell subgroups as indicated. (I) The top 20 differentially expressed genes (based on Wilcoxon test) for each B cell subgroup as indicated. (J) The t‐SNE plots of the B cell biomarkers (MS4A1, CD79A, JCHAIN, and GZMB), colored by the normalized gene expression level in the cells. Resolution used for t‐SNE analysis is 1.0. (K) The total B cell number (left panel) and average cellular proportion (right panel) of distinct subgroups in different tissue types. Epi_P, primary epithelial (adenocarcinoma or squamous) tumor tissue; Epi_LN, lymph node metastatic epithelial (adenocarcinoma or squamous) tumor tissue; NET_P, primary neuroendocrine tumor; NET_LN, lymph node metastatic neuroendocrine tumor; ADJ_N, adjacent normal tissue

Article Snippet: The following antibodies in this study were used: anti‐FOXP3 (mouse, 1:200, ab20034; abcam), CD4 (Rabbit, 1:200, ab183685; abcam), and CD8 (Rabbit, 1:200, ab237709; abcam).

Techniques: Expressing, Two Tailed Test

Journal: Translational Vision Science & Technology

Article Title: A Subsequent Human Neural Progenitor Transplant into the Degenerate Retina Does Not Compromise Initial Graft Survival or Therapeutic Efficacy

doi: 10.1167/tvst.4.1.7

Figure Lengend Snippet: Confocal analysis of retinal morphology and transplant phenotype after subretinal hNPCctx injection. (A) Retinal cryosection stained with HuNu (green, arrows) and DAPI (blue) shows that injected hNPCctx were located between the RPE and ONL in the subretinal space (debris layer). (B) Cone photoreceptor cells, labeled with an antibody against arrestin (red), showed a fairly normal morphology in the treated retina (double arrows). (C, D) Immunolabeling hNPCctx-treated retinas with antibodies against recoverin (red) and HuNu (green, arrows) showed no overlapping label between photoreceptor cells and hNPC, suggesting that hNPCctx were not differentiating into photoreceptor cells. (E) Immunostaining the treated retina with antibodies against vimentin (red) and GFAP (green), both specific Müller glial cell markers, showed that donor cells only expressed GFAP. (F) Immunostaining the treated retina with antibodies against human nestin (green) and Ki67 (red) showed only a few Ki67-positive cells within the grafts (arrows). Scale bar = 100 μm.

Article Snippet: Primary antibodies against the following proteins were used: Recoverin (rabbit, 1:2000; Millipore, Billerica, MA), Arrestin (rabbit, 1:1000; Millipore), human nuclear marker, MAB1281 (mouse, 1:300; Millipore), Ki67 (rabbit, 1:500; Millipore), Nestin (rabbit, 1:2000; Millipore), glial fibrillary acidic protein (GFAP; rabbit, 1:1000; Sigma, Sigma-Aldrich, St. Louis, MO), CD3 (1:1000), CD4 (1:100), and CD8 (1:200; CD3, CD4, and CD8 are all anti-rat, BD Biosciences, San Jose, CA).

Techniques: Injection, Staining, Labeling, Immunolabeling, Immunostaining

Journal: Translational Vision Science & Technology

Article Title: A Subsequent Human Neural Progenitor Transplant into the Degenerate Retina Does Not Compromise Initial Graft Survival or Therapeutic Efficacy

doi: 10.1167/tvst.4.1.7

Figure Lengend Snippet: Confocal analysis of retinal morphology and transplant phenotype after subretinal hNPCctx injection. (A) Retinal cryosection stained with HuNu (green, arrows) and DAPI (blue) shows that injected hNPCctx were located between the RPE and ONL in the subretinal space (debris layer). (B) Cone photoreceptor cells, labeled with an antibody against arrestin (red), showed a fairly normal morphology in the treated retina (double arrows). (C, D) Immunolabeling hNPCctx-treated retinas with antibodies against recoverin (red) and HuNu (green, arrows) showed no overlapping label between photoreceptor cells and hNPC, suggesting that hNPCctx were not differentiating into photoreceptor cells. (E) Immunostaining the treated retina with antibodies against vimentin (red) and GFAP (green), both specific Müller glial cell markers, showed that donor cells only expressed GFAP. (F) Immunostaining the treated retina with antibodies against human nestin (green) and Ki67 (red) showed only a few Ki67-positive cells within the grafts (arrows). Scale bar = 100 μm.

Article Snippet: Primary antibodies against the following proteins were used: Recoverin (rabbit, 1:2000; Millipore, Billerica, MA), Arrestin (rabbit, 1:1000; Millipore), human nuclear marker, MAB1281 (mouse, 1:300; Millipore), Ki67 (rabbit, 1:500; Millipore), Nestin (rabbit, 1:2000; Millipore), glial fibrillary acidic protein (GFAP; rabbit, 1:1000; Sigma, Sigma-Aldrich, St. Louis, MO), CD3 (1:1000), CD4 (1:100), and CD8 (1:200; CD3, CD4, and CD8 are all anti-rat, BD Biosciences, San Jose, CA).

Techniques: Injection, Staining, Labeling, Immunolabeling, Immunostaining